OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

Clinical trial NCT02161562 · COMPLETED

Trial details

NCT number: NCT02161562
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Spontaneous Urticaria

Start date: 2014-08-01
Primary completion: 2016-11-03
Enrollment: 314

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.